help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on July 26, 2005
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-0531
A more recent version of this article appeared on October 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/10/5627    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jørgensen, J. O. L.
Right arrow Articles by Ørskov, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jørgensen, J. O. L.
Right arrow Articles by Ørskov, H.

Submitted on March 11, 2005
Accepted on July 19, 2005

Cotreatment of Acromegaly with a Somatostatin Analogue and a Growth Hormone Receptor Antagonist

Jens Otto Lunde Jørgensen*, Ulla Feldt-Rasmussen, Jan Frystyk, Jian-Wen Chen, Lars Østergård Kristensen, Claus Hagen, and Hans Ørskov

Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus (J.O.L.J, J.F, J.-W.J, H.Ø.), and Rigshospitalet, Copenhagen, (U. F.-R.), and Herlev Sygehus, Copenhagen, (L.Ø.K.), and Odense University Hospital, Odense, (C. H.), Denmark

* To whom correspondence should be addressed. E-mail: jolj{at}dadlnet.dk.

Context: Pegvisomant is a GH receptor antagonist, which blocks the peripheral actions of GH in acromegaly. Pegvisomant, in contrast to somatostatin analogs (SMS), does not suppress the activity of the GH producing adenoma.

Objective: We assessed the effects of cotreatment with pegvisomant and SMS in acromegaly on GH secretion, IGF-I levels and glucose tolerance.

Design, patients, and interventions: 11 patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6 weeks treatment with 10 mg pegvisomant/d, 4) six weeks treatment with 15 mg pegvisomant/d, 5) 3 months treatment with 15 mg pegvisomant plus SMS. Blood was sampled in the fasting state and during an OGTT.

Results: Total serum IGF-I levels (µg/l) decreased following pegvisomant, but the lowest levels were obtained with cotreatment [458 ± 67 (SMS), 562 ± 78 (active), 376 ± 51 (10 mg), 269 (15 mg), 195 ± 24 (combined) (P < 0.0001)]. Free and bioactive IGF-I changed in a similar pattern. Steady-state pegvisomant levels (µg/l) were obtained, but SMS cotreatment increased pegvisomant levels by 20% (P = 0.02) [2631 ± 616 (10 mg), 6536 ± 1413 (15 mg), 8030 ± 1914 (combined)]. Pegvisomant increased endogenous GH levels (µg/l), which was countered by SMS cotreatment [5.1 ± 1.3 (SMS), 8.9 ± 2.9 (active), 14.6 ± 4.9 (10 mg), 19.7 ± 6.5 (15 mg), 11.8 ± 2.8 (combined) (P < 0.01)]. Plasma glucose levels (mmol/l) were highest during SMS and lowest during pegvisomant 15 mg [2-h OGTT: 10.3 ± 0.7 (SMS), 8.9 ± 0.7 (active), 7.2 ± 0.7 (10 mg), 6.5 ± 0.5 (15 mg), 8.0 ± 0.8 (combined) (P = 0.02)].

Conclusions: dual blockade of the GH axis with pegvisomant and a somatostatin analog is feasible in acromegaly.
Key words: growth hormone • acromegaly • somavert




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
C. Nielsen, L. C. Gormsen, N. Jessen, S. B. Pedersen, N. Moller, S. Lund, and J. O. L. Jorgensen
Growth Hormone Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background, and Growth Hormone Receptor Blockade
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2842 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. P Matta, E. Couture, L. Cazals, D. Vezzosi, A. Bennet, and P. Caron
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance
Eur. J. Endocrinol., March 1, 2008; 158(3): 305 - 310.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Lindberg-Larsen, N. Moller, O. Schmitz, S. Nielsen, M. Andersen, H. Orskov, and J. O. L. Jorgensen
The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1724 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Melmed
Acromegaly
N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. O. Akintoye, M. H. Kelly, B. Brillante, N. Cherman, S. Turner, J. A. Butman, P. G. Robey, and M. T. Collins
Pegvisomant for the Treatment of gsp-Mediated Growth Hormone Excess in Patients with McCune-Albright Syndrome
J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2960 - 2966.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Colao, R. Pivonello, R. S Auriemma, M. C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I. A Kourides, C. J Strasburger, et al.
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Eur. J. Endocrinol., March 1, 2006; 154(3): 467 - 477.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society